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poglycemic therapy is crucial for good glycemic control, this study aimed to com-
pare medication adherence to oral hypoglycemic therapy, as well as diabetic care
and risk of acute complications between type II diabetics with schizophrenia ver-
sus those without schizophrenia.METHODS: This study used the National Health
Insurance claims data of a randomly selected sample. Enrollees who had received
oral hypoglycemic therapy in 2002 and had been diagnosed with schizophrenia
were included in the study (the case group). Enrollees without schizophrenia who
had received oral hypoglycemic therapy in 2002were selected tomatch the age and
gender of the case group (1:3) (the comparison group). All subjects were observed
for one year after their index dates – the dates of their first filled prescriptions in
2002. Medication possession ratio (MPR) was measured as MPR0.8 indicated poor
adherence. Indicators of diabetic care included blood glucose test and HbA1c test.
Acute complicationswere defined as emergency roomvisits or hospital admissions
due to coma, hypoglycemia, hyperglycemia, or diabetic ketoacidosis. Logisticmod-
els were used to evaluate likelihood of poor medication adherence and access to
diabetic care. Cox proportional hazards model was adopted to assess risk of acute
complications. RESULTS: There were 202 and 606 subjects in the case group and
comparison group, respectively. The mean age was 52, and 48% were male. Ap-
proximately half of both groups were poorly adherent to their oral hypoglycemic
therapy. Diabetics with schizophrenia were less likely to receive HbA1c test. Their
risks of acute complications were comparable. CONCLUSIONS: According to our
preliminary results, diabetics with schizophrenia, compared with those without
such a condition, had worse diabetic care. Better disease management will be
necessary for this patient group.
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DEMENTIA AND ALZHEIMER’S DISEASE IN CHINA: CHARACTERIZATION AND
CAREGIVER BURDEN
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OBJECTIVES:The impact of dementia andAlzheimer’s disease (AD) are devastating
onmany levels, including the effects on the families/caregivers of the patient. This
study was designed to describe and evaluate the characteristics of a cohort of
Chinese dementia patients, including associated caregivers’ burden.METHODS: A
3-month open-enrollment, multi-center study was conducted at 48 tier 3 hospitals
across mainland China in 2009. Caregivers who accompanied dementia patients
were asked to participate in the caregiver assessment survey. Interviews included
information on caregiver profile, patient care, and caregivers’ burden. Caregiver
burden was measured using the Chinese version of the validated Zarit Burden
Interview (ZBI). Disease severity was measured by the Clinical Dementia Rating
(CDR). RESULTS: A total of 1425 dementia patients with 1387 associated caregivers
completed the Chinese version of the ZBI. Dementia patients from this cohort were
considered to have mild to moderate dementia (mean CDR score 1.67 [SD0.79]).
ADwas themost commondementia subtype among this cohort (46.7%) followed by
vascular dementia (28.7%). Among the caregivers who participated in this survey:
57% were female, 51% identified as the spouse of the dementia patient, and 67.3%
had been caring for the dementia subject more than one year. Dementia caregiver
burden was mild to moderate (mean total ZBI score of 26.6), regardless of age,
gender, level of education, type of dementia, CDR, and duration of care. The care-
giver burden increases over time and is associated with the progression of the
disease. CONCLUSIONS: Dementia has significant emotional and social impact
(measured by ZBI) on patients and caregivers, regardless of demographics and
geography. In China, these challenges may be mitigated by improving public edu-
cation and increasing public awareness on the signs and symptoms of dementia vs
normal aging.
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RESILIENCE RESOURCES PREDICT HIGHER QUALITY OF LIFE (QOL) AMONG
TAIWANESE DIALYSIS PATIENTS
Cromm K, Lai JCL
City University of Hong Kong, Kowloon Tong, Hong Kong
OBJECTIVES: This study with in-centre haemodialysis patients examined the im-
pact of personal psychological resilience resources, social support, hopefulness,
and perceived loss of control to doctor on mental health outcomes. We hypothe-
sized that resilience resources are the overarching principle determining QOL
among these predictors. METHODS: Non-invasive study with cross-sectional de-
sign, using quantitative data collected from standardized self-report measures
(N294). Predictor variables included: resilience resources (perceived control, op-
timism, self-esteem); social support; loss of control to doctor; hope. Control vari-
ables included: gender; age; relationship, vocational, socio-economic status; living
alone; cultural identity; religious beliefs; and disease-related variables such as
cause of renal failure, number of co-morbidities, time since dialysis onset, trans-
plant status, kidney disease impact. Outcome measure: Mental Composite Score
(MCS) of SF-36v2® health survey. RESULTS: Only questionnaires without missing
data were included in the analysis (n219). Significant relationships (p0.01) were
observed of MCS with employment status (r0.25); socioeconomic status (r.30);
kidney disease impact (r0.60); social support (r0.21); hope (r0.27); loss of con-
trol to doctor (r0.16); self-esteem (r.51); optimism (r0.40); perceived control
(r.40). Hierarchical multiple regressionmodel explained 48 percent of variance in
MCS, F(9,209)23.04, p.01. Demographic variables (block 1, 
R2.12,
F(2,216)15.24, p0.01), disease impact (block 2, 
R2.29, F(1,215)104.15, p0.01),
and resilience resources (block 4, 
R2.08, F(3,209)11.48, p0.01) explained a sig-
nificant portion of variance inMCS. Social support, hopefulness, and perceived loss
of control to doctor (block 3, 
R20.01, F(3,212)0.70) were not able to explain a
significant portion of variance in MCS. CONCLUSIONS: Resilience resources ac-
counted for 8 percent of variance over and above all other predictors. Confirming
the hypothesis, variables such as social support that had predicted mental health
in earlier studies became insignificant. Future research should identify less resil-
ient patients andmake positive psychology approaches available to see if outcome
can be improved in clinical practice.
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IRRATIONAL USE OF STEROIDS: A WARNING FOR THE HEALTH CARE SYSTEM
Jan SU
University of Balochistan, Quetta, Balochistan, Pakistan
OBJECTIVES: To investigate the irrational prescription habit of steroids by medical
practitioners in patients with arthritis and lower back pain in the area.METHODS:
Twenty-nine pharmacies were randomly selected in various areas of the Province
and 321 prescriptions of those patients with complaints of arthritis or lower back
pain were evaluated for use of steroids (corticosteroids). RESULTS: A total of 103
out of 321 prescriptions (about 30 %) were containing corticosteroids and the pa-
tients were using these steroids mostly in an irrational manner. These prescrip-
tions were prescribed by medical practitioners of all specialties including orthope-
dics. A small number of non medical doctors (about 2%) were also responsible for
the steroids prescriptions. CONCLUSIONS: This study indicates that this type of
irrational practice is the reflection of state and regulatory affairs in the country and
this is a warning for all developing countries which need strict regulations for
steroid prescriptions.
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ALENDRONATE USE AND THE RISK OF OSTEONECROSIS OF JAW IN TAIWAN
Huang WF, Lu PY, Hsieh CF
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OBJECTIVES: Using a national database to evaluate the risk of ONJ in osteoporosis
females in Taiwan. METHODS: We used the population-based National Health
Insurance (NHI) database in Taiwan to conduct a retrospective cohort study during
the period from 2000 through 2008. The study population confined to the women
who took alendronate or raloxifene initially from Jan, 2001 to Sep, 2005 and medi-
cation needed to be stably prescribed for 90 days. The measurements of clinical
outcomes includedONJ-diagnosis (ICD-9-CMdiagnosis code 526.4, 526.5, 528.3, and
730.18) and sequestrectomy (NHI payment code: 92025B and 92026B) within 3 years
after stable medication use. Cox’s proportional hazard model was used to analyze
the risk of ONJ development. RESULTS:We identified 23,158 womenwho had been
prescribed either alendronate (n  18,504) or raloxifene (n  4,654). The patients
treated with alendronate were at a higher risk of ONJ-diagnosis compared with the
raloxifene group (hazard ratio [HR]  1.336 [95% CI, 1.100-1.622]). For sequestrec-
tomy, patients took alendronate also had a higher risk than raloxifene group
(HR4.648 [95% CI, 1.120-19.291]). CONCLUSIONS: Patients who took alendronate
had a higher risk of ONJ than raloxifene patients, nomatter from the perspective of
having the diagnosis or performing sequestrectomy. When undertaking the bis-
phophonates treatment, doctors need to pay attention to the oral condition of
patients.
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OBJECTIVES: In this research, anti-inflammatory effect of Stachys Fruticulosa-
M.Bieb. extract was studied in rats. METHODS: The effect of the extract against
acute inflammation was studied by hind paw edema test. Intraperitoneal injection
of different doses (50, 100, 200 and 300 mg/kg) of Stachys Fruticulosa which was
followed by hind paw carageenan injection 1 h later were investigated. The resul-
tant edema was quantified by measuring the hind paw edema with three ways of
measurement: micrometer method, paw circumference (PC), plethysmometer
method. RESULTS: After 2, 4 and 6 h we measured the anti-inflammatory effect of
Stachys Fruticulosa extract. Stachys Fruticulosa extract with doses of 100, 200 and
300 mg/kg and indomethacin at a dose of 5 mg/kg showed significant effect.
CONCLUSIONS: It is concluded that themethanolic extract of Stachys fruticulosa -
M.Bieb. has anti-inflammatory effect which can be used as an alternative for Indo-
methacin for treatment of inflammation. Also it might be advantageous to use this
herbal drug as a synergist for Indomethacin anti-inflammatory effects, to lower the
dosage and consequently.
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A RANDOMIZED, PLACEBO CONTROLLED TRIAL TO COMPARE SAFETY AND
EFFICACY BETWEEN CURCUMA LONGA LINN EXTRACT [NR-INF-02],
GLUCOSAMINE SULPHATE AND COMBINATION OF TWO IN THE TREATMENT
OF PAINFUL KNEE OSTEOARTHRITIS
Kulkarni C1, Madhu K1, Saji M2
1St. John’s Medical College, Bangalore, India, 2St. John’s Medical College & Hospital, Bangalore,
India
OBJECTIVES: Osteoarthritis [OA] a common, chronic disabling condition in ortho-
paedic practice is routinely treated with non-steroidal anti-inflammatory drugs
[NSAIDs] which are often associated with serious adverse reactions while long
term Glucosamine sulphate [GS] is frequently used to halt its progression. Objec-
tive of this studywas to compare safety and efficacy of herbal formulationNRINF02
and Glucosamine sulphate alone and their combination with placebo in treatment
of patientswithOA.METHODS:A randomized, single blind, placebo controlled trial
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was carried out after IERB approval. Total of 120/157 patients 30 each, 56-58 yrs old,
with diagnosis of knee OA, Grade – II / III were randomized to receive total dose of
– placebo 800 mg, NRINF02 (Curcuma longa linn.-standardized extract) 500 mg and
GS 1500 mg and their combination orally, for 42 days with follow-up on 21st and
42nd day. Primary efficacy outcomes were measured using WOMAC, Visual Ana-
logue Scale [VAS], Clinician Global Impression of Change [CGIC] and clinical-exam-
ination and secondary efficacy outcome by recording number of paracetamol tab-
lets as rescue medication. Safety profile was monitored at each clinic visit by
recording adverse reactions. Chi-square test, repeated measures ANOVA and
mixedmodel analysis were performed using SPSS 16.0 and presented as inferential
statistics. RESULTS: Patients on NRINF02 showed significant decrease in -WOMAC
 p  0.05, VAS  p  0.05, CGIC  p  0.001, used lesser number of rescue
medications(p  0.05) and demonstrated greater clinical and subjective improve-
ment compared to placebo group. All study medications demonstrated acceptable
safety profile. CONCLUSIONS: Study patients exhibited acceptable tolerability and
efficacy profile with NRINF02 when assessed using algofunctional indices for OA.
NRINF02 may therefore be considered as an alternative treatment option in pa-
tients intolerant to NSAIDs presenting with uncomplicated knee OA.
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DISEASE BURDEN OF RHEUMATOID ARTHRITIS IN MAINLAND CHINA: A
SYSTEMATIC REVIEW AND META-ANALYSIS
Zeng X1, Dong P2, Xie X3
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OBJECTIVES: To conduct a systematic review to estimate the disease burden of
Rheumatoid Arthritis in Mainland China. METHODS: Publications between 1990
and 2010 were systematically searched from 10 electronic databases. Observa-
tional studies consisting of disease burden of Rheumatoid Arthritis were included.
Data were extracted using a standardized form. Quality of searched publications
was evaluated by the quality rating scale. Meta –analysis of prevalence rates was
conducted using the generic inverse variancemodel.Meta-analysis of SF-36 quality
of life scores were performed to assess 8 dimensions by RevMan5.0 software, with
weightedmean difference (WMD) used as the indicator of intervention effect. Sen-
sitivity analyses were performed to evaluate the impact of different research
qualities. RESULTS: In total, 20 studies were included, which general quality was
evaluated asmoderate. The weighted prevalence was 0.42%(95%CIxF0.39%-0.45%).
The weighted prevalence in females was significantly higher than that in males.
But therewas no statistically significant difference on different periods, or between
the southern and northern sections of Mainland China. Themeta-analysis showed
that there was a statistically significant difference between WMD of the 8 dimen-
sions of the SF-36. Sensitivity analysis showed that the weighted results were
stable. The incidence rate of RA was 14.7/100 000. In some studies, it is estimated
that there was 4.92 healthy life year per patient lost in his life resulting from RA.
CONCLUSIONS: The prevalence of RA in Mainland China is similar to that of west-
ern countries. Considering the high disability risk of RA, additional economics
burden studies, especially indirect burden studies, will be helpful for enhance the
awareness of RA and to provide patients treatment options and support.
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THE MEDICATION COSTS OF RHEUMATOID ARTHRITIS - COMPARING BEFORE
AND AFTER INTRODUCTION OF THE BIOLOGICS
Lang HC1, Lin HY2, Lee SS3, Wu SL4
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OBJECTIVES: Rheumatoid arthritis (RA) is a chronic, autoimmune inflammatory
disease imposing a great burden on individuals and society, highlight by the intro-
duction of new expensive biologics within this decade. This study compared the
trend of health care expenditures and biologics costs due to rheumatoid arthritis
from 1999-2009.METHODS: This studywas based on data from theNational Health
Insurance Research Database (NHIRD) released by the National Health Research
Institute, which representing 99% of the entire population of Taiwan.We identified
all patients by both with a primary diagnosed code ICD-9-CM 714.0 and with RA
Catastrophic Illness certificate. Patients who fulfilled the American College of
Rheumatology criteria for the classification of RA are qualified to register in Cata-
strophic Illness file and can benefit for waiving the outpatient registration fee. The
indication for reimbursement the biologics were DAS28xa5.1 for two continuous
measures 1 month apart in Taiwan. RESULTS: After adjusting by using WHO 2000
population, we found the incidence rate of RA is stable around 0.01% from 1999 to
2009 in Taiwan. However the prevalence rate is increasing from0.07% to 1.13%. The
average annual growth rates of total medication cost for RA patients (51.6%) are
higher than the growth rates of total treatment cost for RA patient (36.7%) during
the study period from 1999 to 2009. In addition, Outpatient drug cost growth rates
(11.5%-44.1%) were much higher than that of inpatient drug growth rates (2.4%-
26.7%) during this period. Enbrel was reimbursed by the National Health Insurance
since 2003 and next year it reflected an 11.6% growth rate in expenditure. Although
there are three biologics reimbursed by NHI for qualified RA patients, Enbrel dom-
inates on the market. CONCLUSIONS: The introduction of biologics may benefit to
the decreasing rate of inpatient admission and costs.
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THE MORTALITY AND COSTS FROM HIP, VERTEBRAL, WRIST AND OTHER
FRACTURES AMONG POSTMENOPAUSAL WOMEN IN TAIWAN
Huang KC1, Chang WL2, Ling YL3, Tang CH1
1Taipei Medical University, Taipei, Taiwan, 2National Yang-Ming University, Taipei, Taiwan,
3The University of Texas at Austin, Austin, TX, USA
OBJECTIVES: To examine the mortality and medical cost during the first and sec-
ond year following fractures among elder women by different age groups.
METHODS: Using the inpatient and outpatient database of National Health Insur-
ance to define new hip fracture (ICD9 code 820, 733.14), vertebral fracture (ICD9
code 805, 806, 733.13), wrist fracture (ICD9 code 813, 733.12) and other fracture (ICD9
code 807, 808, 810, 811, 812, 821, 823, 733.10, 733.11, 733.15, 733.16, 733.19) cases
from 2006 to 2009. We divided age into ten groups between 50-100 years. The HR of
mortality and the incremental costs compared to the population without any frac-
ture history in each group were estimated by cox proportional survival model and
generalized linear model. RESULTS: The HR of mortality after hip fracture in each
group ranged from 19.67 to 1.43 while after vertebral fracture ranged from 5.60 to
1.11. The extra costs (in NTD) of hip fracture during first year in each group were
NT$178 535, NT$158 831, NT$184 334, NT$190 206, NT$179 261, NT$160 565, NT$136
195, NT$136 194, NT$110 476, NT$41 194. In the second year, the extra costs of hip
and clinical vertebral fracture were NT$221 036 and NT$135 912, respectively.
CONCLUSIONS: Hip and vertebral fractures result in significant mortality and
costs. These results indicate potential benefits from interventions aimed at reduc-
ing fracture incidences.
PMS10
HOSPITALIZATION COSTS AND THEIR PREDICTORS IN PATIENTS WITH
RHEUMATOID ARTHRITIS IN URBAN CHINA
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OBJECTIVES: Rheumatoid arthritis (RA) is associated with poor quality of life and
higher health care cost. This study aimed to assess the hospitalization costs of
rheumatoid arthritis (RA) and to characterize predictors of these costs.METHODS:
A total of 676 RA patients were randomly selected by stratified two-stage sampling
from the China Basic Health Insurance database in 2009 and 2008. All information
of patient demographic characters, clinical and costs were collected for the analy-
sis. We used generalized estimating equations to examine potential predictors of
the costs. RESULTS: Among 676 RA patients (mean age 57.8 years; 75.2% female),
Themean hospital length-of-stay was 19.4 days for RA patients with basic medical
insurance for urban employees and 15.0 days for those patients with basic medical
insurance for urban residents. The average inpatient cost was Chinese Yuan (CNY)
8521.5 (median:xx6608.7, IQR:xx4223.5-xx10383.3), higher than those without
RA(CNY7670) and the average drug cost accounts for 49.95%of the total cost (mean:
xx5295.3). Themultiple linear regressions showed that the hospital cost of patients
with basic medical insurance for urban employees had 39.6% higher costs than
those with basic medical insurance for urban residents(P0.001). Patients from
tertiary hospitals had 97.8% higher costs than those from primary hospitals; (P 
0.001) and patients from municipalities had 46.0% higher costs than those from
county-level cities( P  0.01). CONCLUSIONS: Patients with RA is associated with
high hospitalization costs. Costs are now driven predominantly by the cost of
drugs, primarily biologic agents. and sociodemographic characteristics such as
types of health insurance and levels of hospitals also play an important role in
determination of costs.
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OBJECTIVES: Ankylosing spondylitis (AS) is associated with poor quality of life and
higher health care cost. This study aimed to assess the inpatient costs of AS and to
characterize predictors of these costs. METHODS: A total of 560 AS patients were
randomly selected by stratified two-stage sampling from the China Basic Health
Insurance database in 2009. All information of patient demographic characters,
clinical and costs were collected for the analysis. We used generalized estimating
equations to examine potential predictors of the costs. RESULTS: Among 560 AS
patients (mean age 55.7 years;57% female), Themeanhospital length-of-staywas
15.2 days for AS patients with basicmedical insurance for urban employees and 9.8
days for those with basic medical insurance for urban residents(P0.001). The
average inpatient cost was RMB 8173.3 yuan (median:4368.7, IQR:2836.1-7399.7)
and the average medical service cost accounts for 68.0% of the total cost (mean:
5560.5; median:2376.0, IQR:1395.0-3882.7). The multiple linear regressions showed
that the patients from tertiary hospitals had 84.7% higher costs than those from
primary hospitals (P  0.001) , patients from the east area have 30.7% higher costs
than those from the west area ( P  0.01), and patients from municipalities had
72.5% higher costs than those from county-level cities( P  0.05). CONCLUSIONS:
Patients with AS is associated with high hospital costs. Costs are now driven pre-
dominantly by the cost of medical service, and sociodemographic characteristics
such as regions and levels of hospitals also play an important role in determination
of costs.
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COST IMPLICATION OF PRESCRIPTIONS IN PRIVATE AND PUBLIC HEALTH
INSTITUTIONS IN BAYELSA STATE OF NIGERIA
Eniojukan JF1, Orumwense DO2, Obidiya SO1
1Niger Delta University, YENAGOA, Bayelsa State, Nigeria, 2Federal Medical Centre, Yenagoa,
Bayelsa State, Nigeria
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